

# **Commission on Cancer**

**MASSACHUSETTS CHAPTER ACS**

**ANNUAL REPORT TO PROGRAMS**

**DECEMBER 2013**

**Peter Hopewood MD FACS**

# CoC Outstanding Achievement Awards 2012

## **CONGRATULATIONS TO**

Holy Family Hospital & Medical Center  
North Andover, Massachusetts  
CLP Dr. Gentry Thatcher

Newton Wellesley Hospital  
Newton Massachusetts  
CLP Dr. Claire Cronin

# 2013 CoC Paper Competition

## Winning Abstract

### Dr Laura Rosenberg

P3	<b>Abstract Title</b> Sorafenib Suppresses Desmoid Tumor Growth and Invasion via Inhibition of ERK Signaling
	<b>Author Block</b> Laura M. Rosenberg, MD <sup>1</sup> , Monica M. Bertagnolli, MD <sup>2</sup> , Nancy L. Cho, MD <sup>2</sup> <i><sup>1</sup>Massachusetts General Hospital, Boston, MA, <sup>2</sup>Brigham and Women's Hospital, Boston, MA</i>
	<b>Abstract Body</b> <b>Background:</b> Desmoid tumors (DTs) are invasive soft tissue lesions that are primarily treated via wide surgical resection. Medical options are limited for patients with recurrent or unresectable disease. Sorafenib is a multikinase inhibitor that blocks tumor cell proliferation via suppression of the Raf/MEK/ERK signaling cascade. We examined the effects of sorafenib on patient-derived DT cell lines, with the aim of characterizing the efficacy and mechanism of action of sorafenib in DTs. <b>Methods:</b> DT-derived cells were cultured from fresh tumor specimens, resulting in 12 distinct patient-derived cell lines. Cells were treated with sorafenib, and proliferation was measured by CellTiter assay after 72 hours. To assess invasion, DT cells were plated in invasion chambers with 5 $\mu$ M sorafenib for 24 hours. For immunoblot analysis, cells were treated with 5 $\mu$ M sorafenib, and lysates were collected at intervals from 15 minutes to 3 days. <b>Results:</b> Sorafenib (10 $\mu$ M) significantly inhibited proliferation of DT-derived cells, suppressing growth to 27% relative to controls. Invasion assays demonstrated a significant inhibition of DT cell invasion compared to controls. Immunoblot analysis revealed that sorafenib inhibited ERK phosphorylation as early as 30 minutes after treatment, and had a sustained effect with inhibition increasing from 1 day to 3 days after treatment. Total ERK levels remained unchanged. This effect correlated with inhibition of total MEK, Akt, and phospho-Akt (Ser473) levels. <b>Conclusion:</b> Our results demonstrate that sorafenib suppresses proliferation and invasion of DTs via inhibition of ERK signaling. Sorafenib may be a potential therapeutic option in the treatment of desmoid tumors.


# WHAT'S NEW IN THE CoC ?

FIRST THERE WAS      NSQIP

THEN THERE WAS      TQIP

NOW THERE IS .....

# Coming to CoC Programs December 2013



The image shows the cover of the CQIP Annual Report 2013. At the top left, there is a blue banner with the American College of Surgeons logo, the text "AMERICAN COLLEGE OF SURGEONS", the tagline "Inspiring Quality. Higher Standards. Better Outcomes.", and a "100 years" anniversary logo. To the right of this banner is the "CQIP Cancer Quality Improvement Program" logo. Further right is a stylized "CoC" logo. The main body of the cover is light blue and features the large "CQIP" text in a dark blue serif font, with "Cancer Quality Improvement Program" written below it in a smaller, dark blue serif font. In the bottom left corner, there is a dark blue square logo with "NCDB" in white, "CQIP" below it, and a stylized "CoC" logo at the bottom right. In the bottom right area, the text "1 of 1500 CoC Hospitals" is displayed, followed by "[FIN]" and "City, State" in a smaller font. At the very bottom, the text "Annual Report 2013" is written in a large, bold, dark blue serif font.

AMERICAN COLLEGE OF SURGEONS  
Inspiring Quality. Higher Standards. Better Outcomes  
100 years

CQIP  
Cancer Quality Improvement Program

CoC

# CQIP

Cancer Quality Improvement Program

1 of 1500 CoC Hospitals  
[FIN]  
City, State

NCDB  
CQIP  
CoC

## Annual Report 2013

# WHAT IS CQIP ?

EXTENSIVE CANCER QUALITY AND OUTCOME DATA  
BOTH SHORT AND LONG TERM

INDIVIDUALIZED FOR EACH CoC PROGRAM

PROVIDES COMPARISONS TO REGIONAL AND  
NATIONAL DATA

FREE TO ALL CoC ACCREDITED PROGRAMS

# CQIP ABSTRACTS DATA FROM NATIONAL CANCER DATA BASE

## WHAT IS THE NCDB

NCDB STARTED 1988 AND MAINTAINED BY ACS

INCLUDES DATA FROM 1500 CoC PROGRAMS

29 MILLION RECORDS FROM CA REGISTRIES

# Summary of CQIP 2013 Sections

- Cancer Program Volume (2008–2010)
- Cancer Program In/Out Migration (2006–2010)
- Quality Measure Reports
- Volume of Selected Complex Cancer Operations
- 30-Day Mortality after Selected Cancer Operations
- Unadjusted Survival Reports by Stage
- Breast Cancer—additional reports
- Colon Cancer—additional reports
- Non-Small Cell Lung Cancer (NSCLC)—additional reports
- Prostate Cancer—additional reports



American College of Surgeons  
Advancing Quality,  
Optimizing Access, Better Outcomes

100years

CQIP

Cancer Quality Improvement Program



Commission  
on Cancer®

© American College of Surgeons 2013.—Content cannot  
be reproduced without written permission of the American College of Surgeons.



# HERE ARE SOME EXAMPLES OF THE UPCOMING REPORTS

## Volume and 30-day Mortality After Selected Complex Cancer Operations

### Volume of Selected Operations for Cancer

Cystectomy

Esophagectomy

Gastrectomy

Pancreatectomy

Rectal resection

Lung resection

### 30-day Unadjusted Mortality

Cystectomy

Esophagectomy


Gastrectomy

Pancreatectomy


Rectal resection

Lung resection

# EXAMPLE: # MAJOR RESECTIONS



# MORTALITY RATES IF > 30 RESECTIONS



# UNADJUSTED SURVIVAL RATES NOW ADJUSTED SURVIVAL RATES 2014

## SURVIVAL RATES BY STAGE


BREAST CANCER

COLON CANCER

NON-SMALL CELL LUNG CANCER

PROSTATE CANCER

# CQIP EXAMPLE BREAST CA SURVIVAL



# MANY REPORTS ARE AVAILABLE

## Prostate Cancer - Additional Reports

- Stage Distribution
- In/Out Migration
- In/Out Migration by Insurance Status
- Race Distribution
- Insurance Status
- Distance Traveled
- First Course of Treatment Stage I and II
- Days to First Treatment: Cases Diagnosed and Treated at My Facility
- Days to First Treatment: Cases Diagnosed at My Facility Elsewhere; Treated at My Facility



American College of Surgeons  
National Cancer  
Quality Improvement Program

ACS

CQIP

Cancer Quality Improvement Program




Commission  
on Cancer®

© American College of Surgeons 2013—Content cannot  
be reproduced without written permission of the American College of Surgeons

# CQIP PROSTATE RX STAGE I&II

## First Course Treatment Stage I & II Prostate Cancer (My Facility vs. All CoC)



	Surgery Only	Radiation Only	Radiation & Hormone Therapy	Hormone Therapy Only	Other Specified Therapy	No 1st Course
Stage I - My Facility	8.9 %	34.2 %	1.3 %	0 %	0 %	55.7 %
Stage I - All CoC	38.4 %	30.9 %	6 %	1.2 %	4.2 %	19.2 %
Stage II - My Facility	49.5 %	18.3 %	10.1 %	0.9 %	0.9 %	20.2 %
Stage II - All CoC	54.2 %	18.5 %	13.4 %	2.3 %	4.4 %	7.1 %




## Breast Cancer - Additional Reports

- Stage Distribution
- In/Out Migration
- In/Out Migration by Insurance Status
- Race Distribution
- Insurance Status
- Distance Traveled
- First Course Treatment – Stage I
- Days to First Treatment: Cases Diagnosed and Treated at My Facility
- Days to First Treatment: Cases Diagnosed at My Facility or Elsewhere; Treated at My Facility
- Radiation Treatment After Breast Cancer Surgery Out Migration Map By Zip Code



# Compares you to all CoC Programs

## Stage Distribution-Breast Cancer Diagnosed in 201 Hospital vs. All CoC)



	0	I	II	III	IV	NA	UNK
<b>My Facility</b>	23.1 %	44.3 %	17.41 %	9.18 %	5.06 %	0.32 %	0.63 %
<b>All CoC</b>	20.57 %	40.58 %	23.7 %	8.53 %	3.86 %	0.09 %	2.67 %



© American College of Surgeons 2012—Content cannot be reproduced without written permission of the American College of Surgeons

## Colon Cancer - Additional Reports


- Stage Distribution
- In/Out Migration
- In/Out Migration by Insurance Status
- Race Distribution
- Insurance Status
- Distance Traveled
- Days to First Treatment: Cases Diagnosed and Treated at My Facility
- Days to First Treatment: Cases Diagnosed at My Facility Elsewhere; Treated at My Facility

## Non–Small-Cell Lung Cancer (NSCLC) - Additional Re

- Stage Distribution
- In/Out Migration Cancer
- In/Out Migration by Insurance Status
- Race Distribution
- Insurance Status
- Distance Traveled
- First Course of Treatment Stage I
- Days to First Treatment: Cases Diagnosed and Treated at My Facility
- Days to First Treatment: Cases Diagnosed at My Facility Elsewhere; Treated at My Facility

# LUNG CA 1<sup>ST</sup> RX STAGE I

## First Course Treatment Stage I Non-small Cell Lung Cancer, 2011



National Cancer

	Surgery Only	Radiation Only	Surgery & Chemotherapy	Radiation & Chemotherapy	Chemotherapy Only	Surgery, Radiation & Chemotherapy	Other Specified Therapy	No 1st Co Rx
<b>My Facility</b>	48.8 %	29.3 %	0 %	7.3 %	0 %	2.4 %	0 %	12.2 %
<b>All CoC</b>	60.5 %	17.5 %	4.3 %	2.9 %	1.6 %	1.4 %	3 %	8.8 %



American College of Surgeons  
 Advancing Quality  
 Improving Lives

100years

**CQIP**


Cancer Quality Improvement Program



Commission  
 on Cancer®

© American College of Surgeons 2012—Content cannot be  
 reproduced without written permission of the American

# COMING TO ALL CoC PROGRAMS DECEMBER 2013



Thank you for not smoking

